HC Wainwright & Co. Maintains Buy on Gritstone Bio, Lowers Price Target to $4
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Sean Lee maintains a Buy rating on Gritstone Bio (NASDAQ:GRTS) but lowers the price target from $7 to $4.

May 13, 2024 | 11:03 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Gritstone Bio's Buy rating is maintained by HC Wainwright & Co., but the price target is reduced from $7 to $4, indicating a potential downside according to the analyst's view.
The maintenance of a Buy rating suggests continued confidence in Gritstone Bio's fundamentals or growth prospects. However, the significant reduction in the price target could reflect new data or analysis that suggests a lower future valuation, potentially leading to short-term negative sentiment among investors.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100